Clarivate identifies radioligand therapy innovators as companies to watch in the future of precision oncology

New report highlights emerging leaders advancing next-generation radiopharmaceuticals, reshaping cancer care through targeted innovation and strategic growth london , june 16, 2025 /prnewswire/ --  clarivate plc (nyse:clvt), a leading global provider of transformative intelligence, today announced the release of a new companies to watch report, radioligand innovators ushering in a new era of precision oncology . the report spotlights pioneering companies that are redefining the drug discovery and development landscape through advancements in radioligand therapies (rlts)—a rapidly evolving class of therapeutics that combines nuclear medicine with precision-targeted biotechnology to treat cancer with heightened specificity.
CLVT Ratings Summary
CLVT Quant Ranking